Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Qana Therapeutics Inc.’s portfolio concerns Biotechnology & Pharmaceuticals and has 1 pending office action. The matter is assigned to 1 distinct examiner and 1 distinct art unit, placing the prosecution activity in one examination channel. This permits counsel to focus directly on the action and on the therapeutic claim features requiring support.
VARADARAJ, ARCHANA is the busiest examiner, with 1 pending matter. The available data shows no additional examiner or art-unit assignment. The practical response is a targeted analysis of the stated grounds, with amendments carefully limited so that the intended biotechnology and pharmaceutical coverage remains meaningful.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415494 | NANOPARTICLES AND METHODS OF USE | VARADARAJ, ARCHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415494 | NANOPARTICLES AND METHODS OF USE | VARADARAJ, ARCHANA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18415494 | NANOPARTICLES AND METHODS OF USE | VARADARAJ, ARCHANA | 1658 | §102§103 | Non-Final OA | — | Pending | Jan 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQana Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Archana Varadaraj has the most, with 1 of Qana Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
